Facing the Pancreatic Dilemma pp 427-432 | Cite as
Gabexate Mesilate and Acute Pancreatitis
Conference paper
Abstract
Despite recent diagnostic improvements and the possibility of benefiting from a more sophisticated form of intensive therapy, acute pancreatitis (AP) is still a major clinical problem with an overall mortality rate of 10 %, as has been the case now for the past 40 years or so [1,2].
Keywords
Acute Pancreatitis Acute Pancreatitis Severe Acute Pancreatitis Multi Organ Failure Necrotic Acute Pancreatitis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References
- 1.Renner IG, Savage WT, III, Pantoja JL et al. (1985) Death due to acute pancreatitis: a retrospective analysis of 405 autopsy cases. Dig Dis Sci 30:1005 –1018PubMedCrossRefGoogle Scholar
- 2.Wilson C, Imrie CW (1991) Current concepts in the management of pancreatitis. Drugs 41: 358–366PubMedCrossRefGoogle Scholar
- 3.Tanaka N, Tsuchiya R, Ishii K (1979) Comparative clinical study of FOY and trasylol in acute pancreatitis. Adv Exp Med Biol 1208:367–377Google Scholar
- 4.Yang CY, Chang-Chien CS, Liaw YF (1987) Controlled trial of protease inhibitor gabexate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas 2:698–700PubMedCrossRefGoogle Scholar
- 5.Goebell H, for the German Pancratitis Study Group (1988) Multicenter double-blind study of gabexate mesilate (FOY), given intravenously in low dose in acute pancreatitis. Digestion 40:83Google Scholar
- 6.Scuro LA, Cavallini G, Bovo P, Riela A, Bassi C et al. (1990) Gabexate mesilate (FOY) treatment of acute pancreatitis. Clin Trials J 27:39–49Google Scholar
- 7.Harada H, Miyake H, Ochi K, Tanaka J, Kimura I (1991) Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol 9:75 – 79PubMedGoogle Scholar
- 8.Valderrama R, Perz Mateo M, Navarro S, Vasquez N, Sanjose L, Adrian MV, Estruch J (1992) Multicenter double-blind trial of gabexate mesilate (FOY) in acute pancreatitis. Digestion 51:65–70PubMedCrossRefGoogle Scholar
- 9.Büchler M, Malfertheiner P, Uhl W, Schölmerich J, Stockman F, et al. (1993) Gabexate mesilate in human acute pancreatitis. Gastroenterology 104:1165–1170PubMedGoogle Scholar
- 10.Pederzoli P, Cavallini G, Falconi M, Bassi C for the Italian GAMEPA Study Group (1993) Gabexate mesilate versus aprotinin in human acute pancreatitis: a prospective, randomized, double-blind multicenter study. Int J Pancreatol 14:117–124Google Scholar
- 11.Scuro LA, Cavallini G (1990) La patologia infiammatoria del pancreas. Nosografia clinica: revisione critica e contribute di gruppo. Relazione al 91 Congresso delia Società Italiana di Medicina Interna. Pozzi, pp 485–634Google Scholar
- 12.Lankisch PG, Pohl V, Goke B, Otto J et al. (1989) Effect of FOY-305 (Camostate) on severe acute pancreatitis in two experimental animal models. Gastroenterology 96:193–199PubMedGoogle Scholar
- 13.Dobosz M, Sledzinski Z, Babicki A, Juszkiewicz P et al. (1992) Synthetic antiproteases in acute pancreatitis: an experimental study. Mt Sinai J Med 59:43–46PubMedGoogle Scholar
- 14.Bradley EL III (1993) A clinically based classification system for acute pancreatitis. Arch Surg 128:586–590PubMedCrossRefGoogle Scholar
- 15.Steinberg W, Schlesselman SE (1987) Tratment of acute pancreatitis. Comparison of animal and human studies. Gastroenterology 93:1420 –1427PubMedGoogle Scholar
- 16.Ranson JHC, Rifkind KM, Roses DF et al. (1974) Prognosis signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet 139:69 – 81PubMedGoogle Scholar
- 17.Bassi C (1994) Classificazione clinica della pancreatite acuta: risultati del Simposio Inter-nazionale di Atlanta. Chirurgia 7:175 –179Google Scholar
- 18.Warshaw A (1993) Damage prevention versus damage control in acute pancreatitis. Gastroenterology 104:1216 –1218PubMedGoogle Scholar
Copyright information
© Springer-Verlag Berlin Heidelberg 1994